Latest News

PDUFA action date of May 28, 2021, assigned by the U.S. Food and Drug Administration San Francisco, California (UroToday.com) — Lantheus Holdings, Inc., the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture, and commercialization of innovative diagnostic and therapeutic agents and products, announced that the U.S. Food and Drug […]

The summary presented herein represents Part I of the two-part series dedicated to the Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline. Part I outlines the appropriate evaluation of the male in an infertile couple.

Male infertility is defined as the inability to conceive following 1 year of regular unprotected intercourse. It is the causative factor in 50% of couples and a leading indication for assisted reproductive techniques (ART).

The summary presented herein represents Part II of the two-part series dedicated to the Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline. Part II outlines the appropriate management of the male in an infertile couple.

It is predicted that erectile dysfunction will affect around 322 million men worldwide by 2025. Because of the large volume of literature on the topic, physicians often turn to systematic reviews and meta-analyses-and particularly abstracts of such articles-for clinical guidance.

To investigate how surgeons approach ethically challenging scenarios that arise in penile prosthesis surgery and identify patient-related factors that impact their approach. A survey was distributed to the Society for Urologic Prosthetic Surgeons membership consisting of six ethically challenging scenarios: an HIV+ patient, a patient with cognitive disability, a registered sex offender, a non-verbal patient, […]

Sildenafil and tadalafil are recommended first line treatment for Erectile Dysfunction (ED). Sildenafil was legally reclassified to a ‘pharmacy’ medicine in the United Kingdom in 2018. To assess the prescribing patterns and costs associated with prescribing of ED drugs in England and to investigate the link between prescribing and deprivation, regional demography and legal reclassification.

Holmium laser enucleation of the prostate (HoLEP) is a highly effective procedure for benign prostatic hyperplasia (BPH) that is size independent and has been recommended for patients requiring antiplatelet (AP) and anticoagulant (AC) medications.

Abnormal intraglandular stromal-epithelial interactions have been known as a main key contributing factor for development of Benign Prostatic Hyperplasia (BPH). However, the underlying mechanism for the dysregulated intercellular communication remains unclear.

Benign prostatic hyperplasia (BPH) is a common multifactorial inflammatory disease of older men, defined by increased growth of prostate epithelial and stromal cells. Elevation serum levels of Interleukin-8 (IL-8), oxidative stress and inflammatory markers represent predictive surrogate markers of the disease progression in smoker BPH patients.